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Some previous reports have suggested that lithium treatment is of 
benefit to women with the premenstrual tension syndrome (PMTS). 
In this study 15 women carefully selected for severe PMTS were 
given lithium carbonate (600-900 mg/day) continuously for three 
menstrual cycles. Lithium did not affect physical Premenstrual 
symptoms and was ineffective in most women against behavioral 
premenstrual symptoms. Despite the low dosage most women also 
experienced significant drug-related side effects. Although a statisti- 
cally significant improvement was recorded by several symptom 
rating instruments, this benefit was of no practical clinical value. 
The three women who responded best to lithium, and who r e  
quested continued treatment beyond 3 months, met diagnostic 
criteria for subsyndromal affective (cyclothymic) disorder. Lithium 
is not recommended for the average woman with PMTS. 
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Given the cyclic nature of the premenstrual tension syndromes (PMTS), it is 
surprising that so little has been reported on the effects of lithium on pre- 
menstrual dysphoria. Sletten & Gershon (1966) reported the first successful 
trial of lithium in this condition. Eight women with irritability, headaches, ex- 
plosive emotional outbursts, tension, insomnia and depression during the pre- 
menstrual period were given 300 mg of lithium carbonate 3 times daily for 
10 days prior to the onset of menses. All eight patients had been previously 
unresponsive to sedatives, diuretics and psychotherapy and were said to have been 
treated successfully with this regimen of lithium for 12-18 months. This was 
an open uncontrolled study and we are unaware of any follow-up reports by this 
group of investigators. Fries (1969) mentioned that lithium had a good effect 
in two out of five women studied for PMTS. Tupin (1972) cites one subject 
with PMTS who improved partly with lithium therapy. There were no detailed 
descriptions of symptomatology, treatment schedule, dosage of lithium or lithium 
plasma levels for either study. Singer et al. (1974) compared lithium with placebo 
in a double-blind multiple random cross-over study involving 19 psychiatric 
outpatients suffering from PMTS. Lithium treatment was given throughout the 
month. Patients improved on both lithium and placebo with no recorded differ- 
ences between treatments. The significance of this study is unclear since 12 of 
their patients were diagnosed as having concomitant, other psychiatric diagnoses 
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(three affective disorders, four neurotics and five remitted schizophrenics). Matts- 
son & von Schoultz (1974) used a double blind cross-over design for a well- 
controlled study of lithium treatment. Eighteen women received 800 mg lithium 
carbonate daily beginning 14 days before the expected first day of menstrual 
flow. Lithium was compared with a diuretic (chlorthalidone) and placebo and 
each treatment was given over two premenstrual periods. All three treatments 
improved the symptoms of PMTS. The rank order of effectiveness was placebo 
first, followed by the diuretic, with lithium least active. Here again the actual 
symptoms described were a mixture of anxiety-depression-irritability-tension to- 
gether with physical complaints. Horrobin et al. (1973) reported the treatment 
of one woman with severe premenstrual edema. She was given 500 mg lithium 
carbonate daily beginning on the day of elevation of basal body temperature 
and continuing until menstruation occurred. She was reported to be free of 
edema for two complete cycles, and the severe dysphoria which usually ac- 
companied the premenstrual edema was also relieved during the lithium trial. 
After 6 months, however, the physical and emotional effectiveness of this treat- 
ment was greatly diminished (Horrobin et al. (1976)). Since much of the avail- 
able evidence is contradictory, we decided to further investigate the possible 
utility of lithium in PMTS. 
METHODS 
Subjects 
Fifteen women suffering severe premenstrual symptoms were selected for this 
study. Their ages were between 27 and 43 (mean 32 years); 14 were married, 
12 with children, and thus constituted a group of mature adult women. They 
all had regular menses, with no significant abnormal findings at physical ex- 
aminations with normal laboratory values, and were completely drug free for 
at least 4 weeks prior to and during the evaluation period. They had pre- 
menstrual dysphoric symptoms for at least six consecutive menstrual cycles. 
Emotional as well as physical symptoms were recorded by the various observers 
and self-rating scales. These were reported as at least “moderate” to “severe” 
during the premenstrual period with “marked” or “complete” relief soon after 
full menstrual flow began. Thus all women studied here suffered a severe pre- 
menstrual dysphoria and the disturbance was definitely an odo f f  phenomenon. 
Procedure 
All subjects were evaluated for at least one complete menstrual cycle before 
beginning treatment. Visits were scheduled to coincide as closely as possible 
with two specific points in the menstrual cycle: a follicular phase visit on Day 9 
(where Day 1 was the onset of menses) and a luteal phase visit on, or around, 
Day 26 but always 2-6 days premenstrual. 
To measure the phenomenology at each visit and record the change occurring 
between the follicular and luteal phases the following rating scales were used: 
1. Visual Analogue Scale (VAS) (Maxwell (1978)). 
2. Menstrual Distress Questionnaire (MDQ) (Moos (1969)). 
3. Multiple Affect Adjective Checklist (MAACL) (Zuckerman & Lubin (1965)). 
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4. State-Trait Anxiety Inventory (STAI) (Spielberger et al. (1970)). 
5. Hamilton Depression Scale (HDS) (Hamilton (1960)). 
6. Carroll Depression Scale (CDS) (Feinberg et al. (1979)). 
The total scores obtained on the various rating scales were used as an index 
of global severity as well as a measure of change between follicular and pre- 
menstrual visits. 
After completion of the initial evaluation (“cycle 0”) all patients were given 
600 mg lithium carbonate daily (300 mg caps. b.i.d.) for one menstrual cycle 
(“cycle 1”). If there was “NO change” in symptomatology after one menstrual 
cycle the dose was increased to 900 mg daily (300 mg t.i.d.) for two additional 
cycles (“cycles 2” and “3”). 
Lithium plasma levels were monitored on each visit to the clinic, i.e. bi- 
monthly. Samples were drawn 12 h after the last dose of the drug was taken 
by the patient. Clinical global impression and side effects were independently 
recorded by the psychiatrist and the research nurse during each visit. 
The rating scale total scores during the premenstrual visit of “cycle 0” were 
compared with the mean total scores for the premenstrual visits of “cycles 1” 
through “3” and analyzed statistically by a 1-way ANOVA. 
RESULTS 
The course of treatment and some of the clinical observations are summarized 
in Table 1. 
All patients received 600-900 mg lithium carbonate daily and the plasma 
lithium levels ranged between 0.3 and 0.85 mEqA (average 0.54). Six patients 
were unable to complete the 3-month study, three because of drug related side- 
effects and three for other reasons. Six patients reported significant side-effects 
but were willing to complete the 3-month schedule. Five patients seemed to 
benefit from the treatment but only three requested to be maintained on lithium 
past the study period. None of the patients experienced any beneficial effects on 
the physical premenstrual symptoms, and in five patients lithium seemed to have 
aggravated the symptoms. 
The change in symptomatology as measured by the various rating scales is 
shown in Table 2. 
Combined Rating Scale total score changes failed to show that lithium car- 
bonate produced a significant beneficial effect (0.087). Comparison of score 
changes on individual rating scales revealed a few in which the difference reached 
a statistical significance. The clinical implications of these results are unclear 
because these instruments were not designed primarily for PMTS (e.g. HDS 
change from 10.5 to 5.0, P < 0.002). 
The VAS and the MDQ give a global measure of PMTS and show some 
degree of statistical significance. This, however, seems to be the result of a 
change from “extremely severe” to “moderate” symptomatology. A final MDQ 
mean score of 114 f 32 or a mean of 43 k 27 on the VAS while on lithium 




































































































































































































































































































































































































































































































































































































Table 2. Lithium trial (n = f.5) 
Rating 
scale 
Pretreatment Treatment mean Significance 









































Total change for the group 0.087 
Table 3. Comparison of ratings in 12 women subjectively unimproved with lithium 
Rating 
scale 
Pretreatment Treatment mean Significance 









































Total change for the group 0.220 
For additional analysis we excluded the three patients who requested to be 
maintained on lithium past the study period (which we interpreted to be a strong 
indication as to the clinical efficacy of the drug in these women) so as to further 
examine the characteristics of definite non-responders. The data for the remain- 
ing 12 subjects are summarized in Table 3. In these 12 patients the changes in 
global symptomatology as rated by the MDQ and the VAS, are statistically non- 
significant. 
As shown in Table 1 only nine patients completed the 3-month treatment trial. 
In Table 4 the premenstrual total scores of the six women who completed the 
study and then withdrew are compared with the scores recorded from the three 
women mentioned earlier who requested to be maintained on lithium beyond 
the study period. 
When the various ratings on these three women are compared with the other 
six women there is no difference whatsoever between the two groups. Thus we 
were unable to show by the instruments used that lithium had a beneficial effect 
on any of the specific premenstrual tension symptoms. 
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Table 4. Average premenstrual scores during treatment for nine women 
who completed the study 
Rating 
scale 
Completed study Completed study 
but declined and requested Significance 
continuation continuation of change 










































A standard procedure for screening and selecting women suffering from severe 
PMTS was utilized in this study. In contrast to anecdotal clinical studies we have 
studied only women who have not experienced major psychiatric disorders in 
the past. Changes in symptomatology and response to treatment were monitored 
with existing validated rating scales in addition to global clinical impressions. 
Most of the women experienced severe side-effects even on low dose lithium, 
reminiscent of observations in normal volunteers (Judd et al. (1977)). The three 
women who clearly benefited from the treatment would probably qualify as 
“subsyndromic” affective disorders (Akiskal et al. (1977)). Two of them had 
first degree relatives with diagnosed affective illness. We believe that these women 
comprise a specific subgroup. Lithium seems to help some cyclothymic features 
without directly affecting their premenstrual tension. Consequently, while on 
lithium they seem to be able to better cope with the PMTS symptoms. The r e  
maining 12 women noted no beneficial effect and most experienced a worsening 
in some of the physical symptoms. We believe that the non-specific emotional 
symptoms which disappeared in some of the women while on lithium cannot 
be completely attributed to a specific effect of medication. A general placebo 
effect seems to play a major role in PMTS treatments (Smith el al. (1975)), the 
full meaning of which needs further clarification. 
Unlike some previously reported studies we were unable to show that lithium 
carbonate is indicated in premenstrual tension syndromes. 
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